Skip to content

Debt-to-equity at other companies

Eli Lilly logo
Eli LillyLLY
1.4×-1.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Viking Therapeutics logo
Viking TherapeuticsVKTX
0.0×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
0.0×
Biogen logo
BiogenBIIB
0.4×+0.1×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
0.2×+0.2×

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.7B+54.2%
Enterprise value$3.35B+37.1%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Current ratio9.3×-0.3×

Where this comes from

Calculated from Denali Therapeutics Inc.’s reported figures.

Based on the most recent quarter.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s debt-to-equity?
Denali Therapeutics Inc. (DNLI) reported debt-to-equity of 0× in Q1 2026.
How has Denali Therapeutics Inc.'s debt-to-equity changed year-over-year?
Denali Therapeutics Inc.'s debt-to-equity decreased by 5.9% year-over-year, from 0× to 0×.
What is the long-term trend for Denali Therapeutics Inc.'s debt-to-equity?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s debt-to-equity has grown at a -6.9% compound annual growth rate (CAGR), from 0.1× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.